Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jun 15;10(6):e0130353.
doi: 10.1371/journal.pone.0130353. eCollection 2015.

Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial

Affiliations
Randomized Controlled Trial

Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial

Yulian Zhang et al. PLoS One. .

Erratum in

Abstract

Objectives: To explore the efficacy of Chinese herbal formula compared with donepezil 5 mg/day in patients with mild Alzheimer's disease (AD).

Methods: Patients with mild AD meeting the criteria were randomized into Chinese herbal formula Yishen Huazhuo decoction (YHD) group and donepezil hydrochloride (DH) group during the 24-week trial. The outcomes were measured by ADAS-cog, MMSE, ADL, and NPI with linear mixed-effect models.

Results: 144 patients were randomized. The mean scores of ADAS-cog and MMSE in both YHD group and DH group both improved at the end of the 24-week treatment period. The results also revealed that YHD was better at improving the mean scores of ADAS-cog and MMSE than DH. Linear mixed-effect models with repeated measures showed statistical significance in time × group interaction effect of ADAS-cog and also in time × group interaction effect of MMSE. The data showed YHD was superior to DH in improving the scores and long term efficacy.

Conclusions: Our study suggests that Chinese herbal formula YHD is beneficial and effective for cognitive improvement in patients with mild AD and the mechanism might be through reducing amyloid-β (Aβ) plaque deposition in the hippocampus.

Trial registration: Chinese Clinical Trial Registry ChiCTR-TRC-12002846.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram and disposition of the two groups.
Fig 2
Fig 2. Scores of ADAS-cog, MMSE, ADL, NPI in YHD and DH group.
A. ADAS-cog scores in groups of YHD and DH; B. MMSE scores in groups of YHD and DH; C. ADL scores in groups of YHD and DH; D. NPI scores in groups of YHD and DH.

References

    1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer's & dementia, 2007, 3(3): 186–191. - PubMed
    1. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer J A, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry, 2006,63(2):168–74. - PubMed
    1. Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Archives of Neurology, 2008,65(3):329–34. 10.1001/archneur.65.3.329 - DOI - PubMed
    1. Francis PT, Palmer AM, Snape M, Wilcock GK. The Cholinergic Hypothesis of Alzheimer's Disease: a Review of Progress. Journal of Neurology, Neurosurgery, and Psychiatry, 1999,66(2):137–47. - PMC - PubMed
    1. Hardy J, Allsop D. Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease. Trends in Pharmacological Sciences. 1991,12(10):383–88. - PubMed

Publication types